Key statistics dashboard for Seres Therapeutics, Inc. (MCRB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
Stock Data
| Price | $4.21 |
| Market Cap | $41M |
| Enterprise Value | $81.8M |
| Beta | 0.26 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.74 |
| Price / Book | 1.18 |
| P/S | 21.65 |
| EV/EBITDA | -1.85 |
| EV/Sales | 43.45 |
| EV/FCF | -1.60 |
| P/FCF | -0.79 |
| Earnings Yield | -55.32% |
| FCF Yield | -125.82% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 82.58% |
| EBIT Margin | -2565.96% |
| EBITDA Margin | -2354.86% |
| Operating Margin | -4462.77% |
| Net Margin | -1192.94% |
| Return on Equity | -60.32% |
| Return on Assets | -22.11% |
| Return on Invested Capital | -89.99% |
| Return on Capital Employed | -103.04% |
Financial Health
| Current Ratio | 2.11 |
| Quick Ratio | 2.11 |
| Cash Ratio | 0.78 |
| Debt / Equity | 1.64 |
| Debt / Assets | 55.76% |
| Net Debt / EBITDA | -0.93 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -10.99 |
Per-Share Data
| Revenue per share | 0.20 |
| Book Value per share | 3.58 |
| Cash per share | 1.62 |
| FCF per share | -5.32 |
| Tangible Book Value per share | 3.58 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 3 |
| Sell | 4 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (1-5) | 0.39 |
Related companies: ABOS · ACTU · APLT · CGTX · HURA · INO · IRD
Explore sector: Healthcare · Biotechnology
More sections of MCRB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks